Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findings.
To report on (1) psychometric properties of the Rosenberg Self-Esteem Scale (SES) studied in adolescents with ADHD, (2) correlations of SES with ADHD scale scores, and (3) change in patient-reported self-esteem with atomoxetine treatment. ADHD patients (12-17 years), treated in an open-label study for 24 weeks. Secondary analyses on ADHD symptoms (assessed with ADHD-RS, CGI, GIPD scales) and self-esteem (SES) were performed. One hundred and fifty-nine patients were treated. A dichotomous structure of the SES could be confirmed. Reliability and internal consistency were moderate to excellent. Highest coefficients were found for the correlation between SES and GIPD scores. Self-esteem significantly increased over time, accompanied by an improvement of ADHD symptoms and related perceived difficulties. The Rosenberg SES was shown to be internally consistent, reliable, and sensitive to treatment-related changes of self-esteem. According to these findings, self-esteem may be an important individual patient outcome beyond the core symptoms of ADHD.
Eli Lilly Endowed Chair of Pediatric Psychopharmacology, Department of Child and Adolescent Psychiatry, Central Institute of Mental Health Mannheim, University of Heidelberg, J 5, 68159 Mannheim, Germany. ralf.dittmann@zi-mannheim.de
Ralf W
RW
Dittmann
Peter M
PM
Wehmeier
Alexander
A
Schacht
Martin
M
Lehmann
Gerd
G
Lehmkuhl
D000293:Adolescent; D000294:Adolescent Behavior / Q000187:drug effects*; D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology*; D002648:Child; D005163:Factor Analysis, Statistical; D005260:Female; D006801:Humans; D008297:Male; D010552:Personality Assessment; D025341:Principal Component Analysis; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use*; D011594:Psychometrics; D015203:Reproducibility of Results; D012649:Self Concept; D057566:Self Report; D012720:Severity of Illness Index
D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride